logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Class
    3. GLP-1 Receptor Agonist

    GLP-1 Receptor Agonist class drugs

    FiltersReset Filters
    7 results

    • mounjaro

      (tirzepatide)
      Eli Lilly and Company
      Usage: MOUNJARO® is indicated as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus.

    • ozempic

      (semaglutide)
      Novo Nordisk
      Usage: OZEMPIC is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes. It also reduces the risk of major adverse cardiovascular events and helps in preventing kidney disease progression in patients with type 2 diabetes and chronic kidney disease.

    • rybelsus

      (Oral Semaglutide)
      Novo Nordisk
      Usage: RYBELSUS is indicated for improving glycemic control in adults with type 2 diabetes mellitus, used alongside diet and exercise. It is not recommended for patients with type 1 diabetes mellitus.

    • saxenda

      (liraglutide)
      Novo Nordisk
      Usage: SAXENDA is indicated for weight management in adults and patients aged 12 and older with obesity (≥60 kg) or with overweight plus a weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. Coadministration with other liraglutide-containing products is not recommended.

    • trulicity

      (Dulaglutide)
      Eli Lilly and Company
      Usage: TRULICITY® is indicated as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes mellitus. It also reduces the risk of major cardiovascular events in adults with type 2 diabetes and existing cardiovascular disease or risk factors.

    • victoza

      (liraglutide)
      Novo Nordisk
      Usage: VICTOZA is indicated to improve glycemic control in adults and pediatric patients (10+) with type 2 diabetes mellitus, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Not for use in type 1 diabetes patients or with other liraglutide products.

    • wegovy

      (semaglutide)
      Novo Nordisk
      Usage: WEGOVY is indicated for reducing major cardiovascular event risk in adults with obesity or overweight and cardiovascular disease, and for long-term weight reduction in adults and pediatric patients (12 years and older) with obesity or adults with overweight and weight-related comorbidities, alongside diet and exercise.